

REMARKS

Applicants respectfully request entry of the above amendment under 37 CFR § 1.312. Applicants note in this regard that the above amendment to allowed claim 18, and the addition of new claims 20-23, are made solely to separate elements (a) thru (e) of allowed claim 18 into separate independent claims. Accordingly, this amendment raises no new issues for substantive consideration.

Applicants note that the Examiner did not acknowledge two U.S. references on Form PTO-1449 that accompanied the Third Supplemental Information Disclosure Statement dated December 2, 2004. Applicants enclose herewith a copy of Form PTO-1449 that was provided with the Notice of Allowance and respectfully request that the Examiner acknowledge U.S. Patent No. 6,329,505 to Xu et al. (Sheet 1 of 9 of Form PTO-1449) and U.S. Patent No. 5,786,149 to Bandman et al. (Sheet 4 of 9 of Form PTO-1449).

In addition, as noted in the amendments to the specification above, the cross reference to the related applications section has been amended to update the priority information for the application such that the earliest claim to priority corresponds to Application Serial No. 09/593,793, filed June 13, 2000. Applicants note that Application Serial No. 09/593,793 describes the identification of the claimed immunogenic fragment referred to as "peptide 4" (SEQ ID NO: 781) which corresponds to residues 160-174 of SEQ ID NO: 525 (*e.g.*, Example 10; page 155, lines 5-9), as claimed in new claim 23. In addition, Application Serial No. 09/605,783, filed June 27, 2000, describes the identification of the claimed immunogenic fragments corresponding to amino acid residues 110-124 of SEQ ID NO: 525 (*e.g.*, Example 10; page 158, lines 4-5), residues 125-139 of SEQ ID NO: 525 (*e.g.*, Example 10; page 158, lines 6-7) and residues 135-149 of SEQ ID NO: 525 (*e.g.*, Example 10; page 158, lines 7-9), as claimed in pending claim 18 and new claims 20 and 21, respectively. In addition, Application Serial No. 09/780,669, filed February 9, 2001, describes the identification of the claimed immunogenic fragment corresponding to amino acid residues 155-170 of SEQ ID NO: 525 (*e.g.*, Example 10; page 158, lines 26-28), as claimed in new claim 22.

Favorable consideration and entry of this Amendment are earnestly solicited.

The Director is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC

A handwritten signature in black ink, appearing to read 'Jeffrey E. Hundley', is written over a horizontal line.

Jeffrey E. Hundley, Ph.D.  
Registration No. 42,676

JEH:teb

Enclosure:

Postcard  
PTO-Form 1449

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

598042\_1.DOC

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

## THIRD SUPPLEMENTAL

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	6,329,505	12/11/01	Xu et al.	530	350	
AB						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
See	AC	WO 99/67384	12/29/99	WIPO		
	AD	WO 00/53772	09/14/00	WIPO		
	AE	WO 00/53776	09/14/00	WIPO		
	AF	WO 00/71711	11/30/00	WIPO		
	AG	WO 00/73801	12/07/00	WIPO		
	AH	WO 01/16289	03/08/01	WIPO		
	AI	WO 01/23587	04/05/01	WIPO		
	AJ	WO 01/25446	04/12/01	WIPO		
	AK	WO 01/57272	08/09/01	WIPO		
✓	AL	WO 02/077243	10/03/02	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

See	AP	Nelson, P.S. et al., "Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression," <i>Proc. Natl. Acad. Sci. USA</i> 96: 3114-3119, March 1999.
	AQ	Stephenson, S-A., "Localization of a New Prostate-specific Antigen-related Serine Protease Gene, <i>KLK4</i> , Is Evidence for a Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3-13.4," <i>The Journal of Biological Chemistry</i> 274(33): 23210-23214, August 13, 1999.
✓	AR	Yousef, G. M. et al., "Protease/ <i>KLK-L1</i> Is a New Member of the Human Kallikrein Gene Family, Is Expressed in Prostate and Breast Tissues, and Is Hormonally Regulated," <i>Cancer Research</i> 59: 4252-4256, September 1, 1999.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SC	BC	GenBank Database, Accession No. AAD26424, October 27, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BD	GenBank Database, Accession No. AAD38019, October 15, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BE	GenBank Database, Accession No. AAF70620, July 10, 2000. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BF	GenBank Database, Accession No. AAF81227, July 2, 2000. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BG	GenBank Database, Accession No. AAG43246, January 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BH	GenBank Database, Accession No. AAK71700, August 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BI	GenBank Database, Accession No. AAK71701, August 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BJ	GenBank Database, Accession No. AAK71702, August 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BK	GenBank Database, Accession No. AAK71703, August 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BL	GenBank Database, Accession No. AAK71704, August 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BM	GenBank Database, Accession No. AAK71705, August 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BN	GenBank Database, Accession No. AAK71706, August 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
CB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CC	GenBank Database, Accession No. AF113140, March 25, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CD	GenBank Database, Accession No. AF126401, January 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CE	GenBank Database, Accession No. AF135023, October 27, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CF	GenBank Database, Accession No. AF228497, July 10, 2000. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CG	GenBank Database, Accession No. AF243527, November 21, 2000. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CH	GenBank Database, Accession No. AF259969, July 2, 2000. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CI	GenBank Database, Accession No. NM_004917, October 27, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CJ	GenBank Database, Accession No. NP_004908, October 27, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CK	GenBank Database, Accession No. XP_008997, May 2, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CL	GenBank Database, Accession No. XP_031752, October 16, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
CM	
CN	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

JUN 06 2005

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA	5,786,148	07/28/98	Bandman et al.	435	6	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DB	DE 19649207	11/27/96	Germany		X
	DC	EP 317,141 A2	05/24/89	EPO		
	DD	EP 652,014 A1	5/10/95	EPO		
get	DE	EP 679,716 A1	11/02/95	EPO		
	DF	EP 936,270 A2	08/18/99	EPO		X
	DG	WO 93/14755	08/05/93	PCT		
	DH	WO 93/25224	12/23/93	PCT		
	DI	WO 94/09820	05/11/94	PCT		
	DJ	WO 95/04548	02/16/95	PCT		
	DK	WO 95/14772	06/01/95	PCT (Cover page with English abstract only)		X
	DL	WO 95/30758	11/16/95	PCT		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DM	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
	DN	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
	DO	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
	DP	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
	DQ	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not eligible is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Enclose copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335610938US

JUN 06 2005

Sheet 5 of 9

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.427C26

APPLICATION NO.

09/895,814

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	EB	WO 96/21671	07/18/96	PCT		
	EC	WO 97/33909	09/18/97	PCT		
	ED	WO 98/2302	03/26/98	PCT		
	EE	WO 98/17687	04/30/98	PCT		
	EF	WO 98/20117	05/14/98	PCT		
SM	EG	WO 98/31799	07/23/98	PCT		
	EH	WO 98/37093	08/27/98	PCT		
	EI	WO 98/37418	08/27/98	PCT		
	EJ	WO 98/38310	09/03/98	PCT		
	EK	WO 98/39446	09/11/98	PCT		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EL	Busselmakers et al., Genbank, Accession No. AF103908, August 14, 2000.
EM	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.
EN	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
EO	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
EP	Database EMBL Accession No. AA453562, June 11, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
SM	FB	WO 98/45435	10/15/98	PCT		
	FC	WO 98/50567	11/12/98	PCT		
	FD	WO 99/06548	02/11/99	PCT		
	FE	WO 99/06552	02/11/99	PCT		
	FF	WO 99/06550	02/11/99	PCT		
	FG	WO 99/25825	05/27/99	PCT		
	FH	WO 99/31236	06/24/99	PCT		
	FI					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FJ	Derwent Geneseq Database, Accession No. V58522, December 8, 1998.
FK	Derwent Geneseq Database, Accession No. V61287, January 6, 1999.
FL	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent 19649201 C1.
FM	El-Shirbiny, "Prostatic Specific Antigen," <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.
FN	Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.
FO	GenBank Accession Number AF047020, February 1, 1999.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not it is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
GB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SC	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 $\alpha$ in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
GD	Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.
GE	Hillier et al., Genbank Accession No. AA100799, December 23, 1997.
GF	Hillier et al., Genbank Accession No. R20590, April 18, 1995.
GG	Hudson, T., Genbank Accession No. G22461, May 31, 1996.
GH	Kroger, B. "New serine protease from human prostate, useful for identifying specific inhibitors, antibodies and probes," <i>Derwent World Patent Index</i> , Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
GI	Lalvan et al., "Rapid effector function in CD8 <sup>+</sup> memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 15, 1997.
GJ	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.
GK	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.
GL	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
HB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HC	National Cancer Institute Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.
HD	Robson et al., "Identification of prostatic adrogen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589, 1995.
HE	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, September 17, 1996.
HF	Schmidt-Wolf et al., "Activated T cells and cytokine-induced CD8 <sup>+</sup> CD56 <sup>+</sup> killer cells," <i>Annals of Hematology</i> 74:51-56, 1997.
HG	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992.
HH	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.
HI	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
HJ	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search," <i>Science</i> 274(5291), 1371-1374, November 22, 1996.
HK	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
HL	Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335610938US

Sheet 9 of 9

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
IA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
IB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IC	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.
ID	Vasmatazis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.
IE	Yee et al., "Isolation of tyrosinase-specific CD8 <sup>+</sup> and CD4 <sup>+</sup> T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.
IF	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.
IG	
IH	
II	
IJ	
IK	
IL	

EXAMINER:

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

US29803

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

### **IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**